The conditions map

Conditions the melanocortin system treats — sorted by how good the evidence actually is

One peptide family, five receptors, and a surprisingly long list of diseases. This is every condition a melanocortin drug treats or is being tested in, sorted into four honest tiers: approved, late-stage, mid-stage, and biology that explains a disease without treating it.

By melanocortin.com editorialLast updated 2026

The same signal, read in the skin, the brain, the adrenal and the gut — which is why the list of diseases looks random until you see the receptors underneath it.

If you came to melanocortins through one door — a tanning peptide, a weight-loss drug, a rare-disease diagnosis — the full list of conditions is a shock. Skin that burns in visible light. A child who never feels full. An adrenal gland that will not stop. An inflamed colon. It reads like four unrelated specialties, and it is one signalling system: a single precursor, POMC, cut into a handful of peptides and read by five receptors in five different places.

That breadth is exactly why this field attracts loose claims. So the list below is sorted by the only thing that should sort it: how far the evidence has actually got. Approved means a regulator signed off.[1][2][3][4] Everything below that line is a bet, and the further down you read, the longer the odds. Each row links to the page that carries its own citations.

Approved

A melanocortin drug is licensed for the condition. The mechanism has survived randomised trials and a regulator.

Late-stage

A Phase 3 trial is running or has read out, with no approval for this condition yet. Close, but not proven.

Mid-stage

Phase 2 or earlier data in patients. Enough to take seriously, not enough to lean on — several of these have already had a miss.

Mechanism, not medicine

The melanocortin system explains the condition, but nothing here is a therapy. Included because the biology is too clean to leave out.

Tried and dropped

A field that only lists its wins is a brochure. These programmes reached patients and were stopped, and each one taught the field something the survivors are built around — above all that pushing MC4R hard enough to matter can also push blood pressure.[9]

  • LY2112688 (mc4r agonist for common obesity). Raised blood pressure and heart rate in a 2009 trial, which set the whole approach back a decade.
  • Intranasal bremelanotide (erectile dysfunction). Halted over blood-pressure increases; the drug was later reformulated as an injection for a different condition.
  • PF-07258669 (oral mc4r antagonist for appetite loss). Stopped in Phase 1 in 2025 for a business decision, not a safety finding.

How to read the pattern

Look down the receptor column and the list stops looking random. The MC4R rows are all about energy balance, run in both directions: agonists where the satiety signal is missing, antagonists where it is jammed on.[8] The MC1R rows split in two — pigment for the light-sensitivity diseases, where an oral agonist is now under regulatory review[5] and a vitiligo trial is fully enrolled,[6] and the receptor's quieter anti-inflammatory job for the gut, the eye and scarring skin, the story told on the inflammation page. The MC2R rows are the newest idea on the board: not adding a signal but blocking one, at the adrenal, in diseases of too much ACTH.[7]

Notice also where the recent approvals sit. The modern ones are rare, and in each the broken step is known: a missing precursor, a receptor that cannot reach its cilium, a pigment response that light itself cannot safely trigger. The ACTH-gel labels for sarcoidosis, MS relapse and infantile spasms are older and broader, and their evidence is thinner. That is the real lesson of the last few years. Melanocortin drugs have worked best as precise repairs to a defined fault, and least well as broad levers on common disease. For the drug-by-drug view of the same landscape, see the pipeline; for the two directions a receptor can be pushed, the agonists and antagonists hubs.

Education, not a protocol

This page maps where the evidence stands. It is not medical advice and gives no dosing, sourcing or treatment guidance. An investigational use is exactly that: unproven. See the editorial standards.

Common questions

What conditions are melanocortin drugs approved to treat?

Five, through three modern drugs: erythropoietic protoporphyria (afamelanotide); obesity from POMC, PCSK1 or LEPR deficiency, Bardet–Biedl syndrome and acquired hypothalamic obesity (setmelanotide); and hypoactive sexual desire disorder in premenopausal women (bremelanotide). An older ACTH preparation, repository corticotropin, also carries long-standing labels for infantile spasms, multiple-sclerosis relapses and sarcoidosis. The relapse and sarcoidosis uses have their own pages.

What conditions are melanocortin drugs being tested for?

In late-stage trials: X-linked protoporphyria, vitiligo, congenital adrenal hyperplasia and dry eye disease. In mid-stage trials: Cushing’s disease, cachexia, ulcerative colitis, rheumatoid arthritis, systemic sclerosis, membranous nephropathy and common obesity. None of these is an approved use, and several have already had a failed or mixed trial.

Why does one hormone system touch such different diseases?

Because the same few peptides are read by five receptors sitting in different tissues. MC1R is on pigment and immune cells, MC2R on the adrenal, MC3R and MC4R in the brain’s energy circuits, MC5R on exocrine glands. A skin disease, an obesity syndrome and an adrenal disorder can all be melanocortin conditions while having nothing else in common.

Does a melanocortin drug approved for one condition work for the others?

No. Each approval covers one specific condition, usually a rare one with a clearly identified break in the pathway. Setmelanotide, for example, works where the signal above MC4R is missing; it is not a treatment for common obesity. The tiers on this page are per condition for exactly that reason.

Is this page medical advice?

No. It is a map of where the evidence stands, kept for readers who want to understand the field. It gives no dosing, sourcing or treatment guidance. Diagnosis and treatment decisions belong with a clinician.

References

  1. 1.StatPearls. Setmelanotide. NCBI Bookshelf (NBK589641) — indications and approval history. 2024. link ↗
  2. 2.Rhythm Pharmaceuticals. FDA approval of IMCIVREE (setmelanotide) for acquired hypothalamic obesity. Press release. 2026. link ↗
  3. 3.HCPLive. FDA approves afamelanotide to treat erythropoietic protoporphyria. News. 2019. link ↗
  4. 4.US FDA. VYLEESI (bremelanotide injection) prescribing information. Label, NDA 210557. 2019. link ↗
  5. 5.Dermatology Times. Dersimelagon NDA accepted by FDA with priority review for EPP, XLP. News report on the 2026 NDA acceptance and review timeline. 2026. link ↗
  6. 6.Dermatology Times. Clinuvel completes enrollment in Phase III afamelanotide vitiligo trial. News report on the CUV105 trial. 2025. link ↗
  7. 7.Merke DP, Auchus RJ. The evolution of new approaches to the treatment of congenital adrenal hyperplasia. Endocr Rev. bnag033 (online ahead of print). 2026. link ↗
  8. 8.Shi J, Xiong J, Hao C, et al. MC4R antagonists: a promising new hope for the treatment of cachexia and wasting diseases. Pharmazie. 81(1–4):51802. 2026. link ↗
  9. 9.Prindle CR, Bennett TL, Rajewski BH, et al. The melanocortin receptors as targets for general obesity: contextualizing clinical failures and analyzing future perspectives. Front Endocrinol (Lausanne). 17:1797586. 2026. link ↗